---
document_datetime: 2025-12-02 05:20:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tolura.html
document_name: tolura.html
version: success
processing_time: 0.14755
conversion_datetime: 2025-12-28 10:13:13.98684
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tolura

[RSS](/en/individual-human-medicine.xml/65492)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tolura](#news-on)
- [More information on Tolura](#more-information-on-tolura-451)
- [More information on Tolura](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Tolura. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tolura.

Expand section

Collapse section

## What is Tolura?

Tolura is a medicine that contains the active substance telmisartan. It is available as white tablets (round: 20 mg; oval: 40 mg; capsule-shaped: 80 mg).

Tolura is a 'generic medicine'. This means that Tolura is similar to a 'reference medicine' already authorised in the European Union (EU) called Micardis.

## What is Tolura used for?

Tolura is used to treat essential hypertension (high blood pressure) in adults. 'Essential' means that the hypertension has no obvious cause.

Tolura is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks. It is used in patients who have had problems due to blood clots in the past (such as heart disease or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).

The medicine can only be obtained with a prescription.

## How is Tolura used?

For the treatment of essential hypertension, the recommended dose of Tolura is 40 mg once a day, but some patients may benefit from using a 20-mg dose. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient's blood pressure closely when starting Tolura, and may decide to adjust the patient's blood pressure-lowering medication.

## How does Tolura work?

The active substance in Tolura, telmisartan, is an 'angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack. It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.

## How has Tolura been studied?

Because Tolura is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Tolura?

Because Tolura is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.

## Why has Tolura been approved?

The CHMP concluded that, in accordance with EU requirements, Tolura has been shown to have comparable quality and to be bioequivalent to Micardis. Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk. The Committee recommended that Tolura be given marketing authorisation.

## Other information about Tolura

The European Commission granted a marketing authorisation valid throughout the EU for Tolura to Krka, d.d., Novo mesto on 4 June 2010. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Tolura, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Tolura : EPAR - Summary for the public

English (EN) (66.29 KB - PDF)

**First published:** 22/06/2010

**Last updated:** 21/07/2011

[View](/en/documents/overview/tolura-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-325)

български (BG) (167.01 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/bg/documents/overview/tolura-epar-summary-public_bg.pdf)

español (ES) (129.91 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/es/documents/overview/tolura-epar-summary-public_es.pdf)

čeština (CS) (96.11 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/cs/documents/overview/tolura-epar-summary-public_cs.pdf)

dansk (DA) (68.6 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/da/documents/overview/tolura-epar-summary-public_da.pdf)

Deutsch (DE) (131.7 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/de/documents/overview/tolura-epar-summary-public_de.pdf)

eesti keel (ET) (127.93 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/et/documents/overview/tolura-epar-summary-public_et.pdf)

ελληνικά (EL) (168.2 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/el/documents/overview/tolura-epar-summary-public_el.pdf)

français (FR) (131.02 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/fr/documents/overview/tolura-epar-summary-public_fr.pdf)

italiano (IT) (131.3 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/it/documents/overview/tolura-epar-summary-public_it.pdf)

latviešu valoda (LV) (155.27 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/lv/documents/overview/tolura-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (152.91 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/lt/documents/overview/tolura-epar-summary-public_lt.pdf)

magyar (HU) (150.72 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/hu/documents/overview/tolura-epar-summary-public_hu.pdf)

Malti (MT) (154.36 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/mt/documents/overview/tolura-epar-summary-public_mt.pdf)

Nederlands (NL) (130.97 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/nl/documents/overview/tolura-epar-summary-public_nl.pdf)

polski (PL) (157.63 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/pl/documents/overview/tolura-epar-summary-public_pl.pdf)

português (PT) (128.48 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/pt/documents/overview/tolura-epar-summary-public_pt.pdf)

română (RO) (93.79 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/ro/documents/overview/tolura-epar-summary-public_ro.pdf)

slovenčina (SK) (153.75 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/sk/documents/overview/tolura-epar-summary-public_sk.pdf)

slovenščina (SL) (89.6 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/sl/documents/overview/tolura-epar-summary-public_sl.pdf)

Suomi (FI) (128.35 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/fi/documents/overview/tolura-epar-summary-public_fi.pdf)

svenska (SV) (67 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

21/07/2011

[View](/sv/documents/overview/tolura-epar-summary-public_sv.pdf)

## Product information

Tolura : EPAR - Product Information

English (EN) (236.58 KB - PDF)

**First published:** 22/06/2010

**Last updated:** 18/07/2025

[View](/en/documents/product-information/tolura-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-152)

български (BG) (272.42 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/bg/documents/product-information/tolura-epar-product-information_bg.pdf)

español (ES) (248.31 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/es/documents/product-information/tolura-epar-product-information_es.pdf)

čeština (CS) (246.14 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/cs/documents/product-information/tolura-epar-product-information_cs.pdf)

dansk (DA) (255.09 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/da/documents/product-information/tolura-epar-product-information_da.pdf)

Deutsch (DE) (259.91 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/de/documents/product-information/tolura-epar-product-information_de.pdf)

eesti keel (ET) (237.25 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/et/documents/product-information/tolura-epar-product-information_et.pdf)

ελληνικά (EL) (275.91 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/el/documents/product-information/tolura-epar-product-information_el.pdf)

français (FR) (252.54 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/fr/documents/product-information/tolura-epar-product-information_fr.pdf)

hrvatski (HR) (250.4 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/hr/documents/product-information/tolura-epar-product-information_hr.pdf)

íslenska (IS) (249.11 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/is/documents/product-information/tolura-epar-product-information_is.pdf)

italiano (IT) (240.16 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/it/documents/product-information/tolura-epar-product-information_it.pdf)

latviešu valoda (LV) (250.46 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/lv/documents/product-information/tolura-epar-product-information_lv.pdf)

lietuvių kalba (LT) (255.78 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/lt/documents/product-information/tolura-epar-product-information_lt.pdf)

magyar (HU) (256.37 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/hu/documents/product-information/tolura-epar-product-information_hu.pdf)

Malti (MT) (302.72 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/mt/documents/product-information/tolura-epar-product-information_mt.pdf)

Nederlands (NL) (261.17 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/nl/documents/product-information/tolura-epar-product-information_nl.pdf)

norsk (NO) (236.82 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/no/documents/product-information/tolura-epar-product-information_no.pdf)

polski (PL) (272.96 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/pl/documents/product-information/tolura-epar-product-information_pl.pdf)

português (PT) (244.58 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/pt/documents/product-information/tolura-epar-product-information_pt.pdf)

română (RO) (252.97 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/ro/documents/product-information/tolura-epar-product-information_ro.pdf)

slovenčina (SK) (261.32 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/sk/documents/product-information/tolura-epar-product-information_sk.pdf)

slovenščina (SL) (237.48 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/sl/documents/product-information/tolura-epar-product-information_sl.pdf)

Suomi (FI) (242.03 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/fi/documents/product-information/tolura-epar-product-information_fi.pdf)

svenska (SV) (244.79 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

18/07/2025

[View](/sv/documents/product-information/tolura-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000279934 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tolura : EPAR - All Authorised presentations

English (EN) (52.04 KB - PDF)

**First published:** 22/06/2010

**Last updated:** 16/09/2020

[View](/en/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-835)

български (BG) (53.8 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/bg/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_bg.pdf)

español (ES) (52.61 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/es/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.3 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/cs/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.79 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/da/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.97 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/de/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.28 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/et/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.61 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/el/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_el.pdf)

français (FR) (54.23 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/fr/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.89 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/hr/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (51.07 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/is/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.37 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/it/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.58 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/lv/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.89 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/lt/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (55.17 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/hu/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (52.43 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/mt/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.02 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/nl/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.05 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/no/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.66 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/pl/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.52 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/pt/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.75 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/ro/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.54 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/sk/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/sl/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (51.92 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/fi/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.7 KB - PDF)

**First published:**

22/06/2010

**Last updated:**

16/09/2020

[View](/sv/documents/all-authorised-presentations/tolura-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tolura Active substance telmisartan International non-proprietary name (INN) or common name telmisartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA07

### Pharmacotherapeutic group

Angiotensin II antagonists, plain

### Therapeutic indication

**Hypertension**

Treatment of essential hypertension in adults.

**Cardiovascular prevention**

Reduction of cardiovascular morbidity in patients with:

- manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;
- type 2 diabetes mellitus with documented target organ damage.

## Authorisation details

EMA product number EMEA/H/C/001196

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Krka, d.d., Novo mesto

Opinion adopted 18/03/2010 Marketing authorisation issued 04/06/2010 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tolura : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.98 KB - PDF)

**First published:** 19/03/2025

**Last updated:** 18/07/2025

[View](/en/documents/procedural-steps-after/tolura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tolura : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (218.1 KB - PDF)

**First published:** 21/07/2011

**Last updated:** 19/03/2025

[View](/en/documents/procedural-steps-after/tolura-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tolura-H-C-1196-A31-0013 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommenda...

English (EN) (48.81 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_en.pdf)

[Other languages (22)](#file-language-dropdown-693)

български (BG) (87.49 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/bg/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/es/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/cs/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/da/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/de/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/et/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/el/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fr/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hr/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/it/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lv/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lt/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hu/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/mt/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/nl/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pl/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pt/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/ro/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sk/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sl/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fi/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sv/documents/scientific-conclusion/tolura-h-c-1196-a31-0013-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sv.pdf)

## Initial marketing authorisation documents

Tolura : EPAR - Public assessment report

English (EN) (181.52 KB - PDF)

**First published:** 22/06/2010

**Last updated:** 22/06/2010

[View](/en/documents/assessment-report/tolura-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Tolura

Adopted

Reference Number: EMA/CHMP/143991/2010

English (EN) (49.42 KB - PDF)

**First published:** 19/03/2010

**Last updated:** 19/03/2010

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-tolura_en.pdf)

#### News on Tolura

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Tolura

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Tolura

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/07/2025

## Share this page

[Back to top](#main-content)